A retrospective study of biological agents in prevalence of SARS-CoV-2 infection among patients who reported respiratory symptoms during COVID-19 pandemic
Latest Information Update: 15 Jan 2021
Price :
$35 *
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Baricitinib (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
- Indications COVID 2019 infections; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Severe acute respiratory syndrome; Spondylarthritis
- Focus Therapeutic Use
- 15 Jan 2021 New trial record